These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29802225)

  • 1. TRKA expression and
    Mauri G; Valtorta E; Cerea G; Amatu A; Schirru M; Marrapese G; Fiorillo V; Recchimuzzo P; Cavenago IS; Bonazzina EF; Motta V; Lauricella C; Veronese S; Tosi F; Maiolani M; Rospo G; Truini M; Bonoldi E; Christiansen J; Potts SJ; Siena S; Sartore-Bianchi A
    J Clin Pathol; 2018 Oct; 71(10):926-931. PubMed ID: 29802225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
    Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
    Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer.
    Choi Y; Won YJ; Lee S; Kim A; Kim Y; Park WY; Jo HJ; Song GA; Kwon CH; Park DY
    Transl Oncol; 2018 Jun; 11(3):764-770. PubMed ID: 29689458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
    Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation.
    Bounacer A; Schlumberger M; Wicker R; Du-Villard JA; Caillou B; Sarasin A; Suárez HG
    Br J Cancer; 2000 Jan; 82(2):308-14. PubMed ID: 10646882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.
    Agaram NP; Zhang L; Sung YS; Chen CL; Chung CT; Antonescu CR; Fletcher CD
    Am J Surg Pathol; 2016 Oct; 40(10):1407-16. PubMed ID: 27259011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic rearrangements of the NTRK1/NGF receptor.
    Pierotti MA; Greco A
    Cancer Lett; 2006 Jan; 232(1):90-8. PubMed ID: 16242838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E; Karbownik M; Migdalska-Sek M; Pastuszak-Lewandoska D; Włoch J; Lewiński A
    Mutat Res; 2006 Jul; 599(1-2):26-35. PubMed ID: 16483615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma.
    Brzeziańska E; Pastuszak-Lewandoska D; Lewiński A
    Neuro Endocrinol Lett; 2007 Jun; 28(3):221-9. PubMed ID: 17627253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma.
    Musholt TJ; Musholt PB; Khaladj N; Schulz D; Scheumann GF; Klempnauer J
    Surgery; 2000 Dec; 128(6):984-93. PubMed ID: 11114633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
    Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
    J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 20. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.